HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

Files in This Item:
BJC104-2_241-247.pdf1.23 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/46823

Title: The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
Authors: Shinohara, Nobuo Browse this author
Takahashi, Masayuki Browse this author
Kamishima, Tamotsu Browse this author
Ikushima, Hitoshi Browse this author
Otsuka, Noriyuki Browse this author
Ishizu, Akihiro Browse this author
Shimizu, Chikara Browse this author
Kanayama, Hiroomi Browse this author
Nonomura, Katsuya Browse this author
Keywords: thyroid atrophy
hypothyroidism
sunitinib
renal cell carcinoma
Issue Date: 18-Jan-2011
Publisher: Nature Publishing Group
Journal Title: British Journal of Cancer
Volume: 104
Issue: 2
Start Page: 241
End Page: 247
Publisher DOI: 10.1038/sj.bjc.6606029
Abstract: Background: In order to elucidate the incidence and the mechanisms of sunitinib-induced thyroid atrophy, we investigated the serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib. Methods: Thyroid volume measured by CT volumetry and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of thyroid gland was performed in 4 autopsied patients. Results: The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n=8; more than 50% reduction in volume) than in the low reduction rate group (n=9; less than 50% reduction in volume). Half of patients in the high reduction rate group exhibited a transient TSH suppression suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland. Conclusion: Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-inuced thyrotoxicosis or the direct effects of sunitinib that leads to degeneration of thyroid follicular cells.
Type: article (author version)
URI: http://hdl.handle.net/2115/46823
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 篠原 信雄

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University